Dividend-paying stocks have consistently attracted investor interest due to their long-term value. CNBC highlights this by ...

SCHD, thanks to its exposure to mature, dividend-paying companies, is withstanding the market shock better. Click here for ...

Happily for investors, Pfizer is generating enough cash flow to cover its dividend. In 2024, it paid $9.5 billion in ...

The old idiom "blink, and you'll miss it" might be the best descriptor of the historic volatility we've witnessed on Wall ...

You may know 175-year-old pharmaceutical company Pfizer (NYSE: PFE) best for its COVID-19 vaccine, but investors have long ...

PFE stock is likely to be a great pick for value investors, considering its cheap valuation, as well as for income investors ...

Pfizer's stock has nosedived over 63% since its post-pandemic peak, scaring off investors like it's contagious. Despite the ...

Pfizer’s blockbuster COVID era has officially left the chat, but the pharmaceutical giant is scripting a bold new chapter.

Buying stock in great companies when they are dealing with some short-term issue that creates stock price weakness can set investors up for big gains down the road. Stocks normally trade at discounts ...

Finally, Pfizer’s massive $43 billion acquisition of cancer treatment innovator Seagen in December 2023 is beginning to pay ...

Communication between health-care professionals and individuals with cancer regarding the effects of treatment on sexual health and fertility has historically been limited. Contemporary studies have ...

The trial was conducted by Seagen in partnership with Genmab, the Gynecologic Oncology Group (GOG) Foundation and the European Network of Gynaecological Oncological Trial Groups, along with other ...